What Sets Us Apart
The Interventional Heart Failure Program provides a robust array of treatments complementing our already strong commitment to advanced heart failure. This multidisciplinary program includes a dedicated nurse navigator, a heart failure advanced practice provider in addition to structural interventionalists and advanced heart failure physicians. It is a hub for the coordinated and seamless treatment of heart failure patients using implantable monitoring devices and interventional protocols.
Innovative interventions for HF include baroreflex activation therapy targeting the activated sympathetic system and investigational devices such as mechanical left ventricular cavity reduction and atrial decompression for HF with reduced and preserved ejection fraction.
Our Team
Our cohesive, multidisciplinary system of care between both Interventional Cardiology and Advanced Heart Failure utilizes a heart-team approach to ensure comprehensive patient evaluations and optimal care determinations. Our combined expertise allows us to offer minimally invasive treatment options not formally available to patients with congestive heart failure and provide a streamlined and enhanced patient journey.
Volume & Quality
The Interventional Heart Failure is a new, first-of-its kind program. This program joins a multidisciplinary service line servicing more than 6,000 patients annually. The volume at our referral center helps us achieve this goal as national data has shown that both high-volume centers and high-volume providers lead to better patient outcomes after cardiac interventions.
Tampa General Hospital is known for providing world-class care and our collaboration with the University of South Florida has placed us at the forefront of innovation in the heart and vascular treatment landscape.
Advanced Technology & Research
The past decade witnessed major advances not only in trans-catheter therapies for structural heart disease such as MitraClip and TAVR, but also with innovative interventions such as baro-reflex activation therapy (BAT) targeting the activated sympathetic system in CHF. Investigational devices such as mechanical left ventricular cavity reduction and atrial decompression for HFREF and HFPEF will take center stage in CHF interventional therapies.
Diseases We Treat
- Moderate to Severe Mitral Regurgitation
- Moderate to Severe Tricuspid Regurgitation
- Heart Failure and Preserved Left ventricular Function (HFpEF)
- Heart Failure and Reduced Ejection Fraction (HFrEF)
Treatments Options
- Transcatheter edge-to-edge mitral valve repair
- Transcatheter edge-to-edge tricuspid valve repair
- Heterotopic tricuspid valve implantation (Compassionate use)
- Left Ventricular Remodeling-Corcinch (Investigational)
- Baro-reflex Activation Therapy (BAT)
- Atrial flow regulation (Investigational)
Clinical Trials
Our nationally renowned physicians are experts in the field of cardiology and thus have access to cutting edge industry and physician-sponsored clinical device trials and studies. These often include the most advanced technologies offered around the world and help establish the future delivery of cardiac disease management. The Interventional Heart Failure Program’s participation in the Corcinch-HF and BAT Wire Implant Kit studies, as well as upcoming studies and trials, will open new doors to treatments options for patients that have never been available.
Our Leadership Team
 |
Dr. Fadi Matar, MD, FACC, FSCAI TGH Cath Lab Director Interventional Heart Failure Program Director, TGH Heart & Vascular Institute Associate Professor, USF Health Morsani College of Medicine |
|
|
Dr. Joel Fernandez, MD, FACC Associate Professor, USF Health Morsani College of Medicine Chief CHF & Cardiomyopathy Section, USF Health Morsani College of Medicine |
|
|
Brenda Garza, BSN RN CCRN IHF Nurse Navigator |
